[EN] OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS [FR] DÉRIVÉS D'OXADIAZOLYLTHIOPHÈNE À UTILISER EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
[EN] COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR<br/>[FR] COMPOSITIONS COMPRENANT UN INHIBITEUR DE PI3K ET UN INHIBITEUR DE HDAC
申请人:KARUS THERAPEUTICS LTD
公开号:WO2017029514A1
公开(公告)日:2017-02-23
The invention relates to a pharmaceutical composition comprising at least one PI3K inhibitor of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor such as a compound of Formula II or a pharmaceutically acceptable salt thereof; or at least one PI3K inhibitor such as a compound of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor of Formula II or a pharmaceutically acceptable salt thereof.
The invention relates to a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of proteasome inhibitors, tumour immunotherapeutics or immunomodulatory agents, signal transduction pathway inhibitors, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.
[EN] NOVEL HISTONE DEACETYLASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
申请人:KARUS THERAPEUTICS LTD
公开号:WO2014181137A1
公开(公告)日:2014-11-13
The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.
本发明是该化合物的化合物或其药学上可接受的盐。这些化合物可用作HDAC抑制剂。
[EN] HDAC INHIBITORS FOR USE IN THE THERAPY OF BILIARY TRACT CANCERS<br/>[FR] INHIBITEURS DE HDAC POUR UNE UTILISATION DANS LE TRAITEMENT DE CANCERS DU TRACTUS BILIAIRE
申请人:KARUS THERAPEUTICS LTD
公开号:WO2021001651A1
公开(公告)日:2021-01-07
The present invention relates to a compound of formula (I), or its pharmaceutically acceptable salt. The compound, or its pharmaceutically acceptable salt, is useful as a HDAC inhibitor and therefore in therapy. In particular, the compound, or its pharmaceutically acceptable salt, has utility in the treatment of biliary tract cancer. (I)
di(2-pyrazyl)amine (Hdpza) (1) and studied its coordination modes and the corresponding complexes with Cu(II), Co(II), Ni(II) and Cr(II). Hdpza is an analogue of the well-studied di(2-pyridyl)amine (Hdpa) ligand, which was used to generate the first extended metal atom chain. Three types of coordination modes were found: anti–anti style which resulted in a mononuclear compound [Cu(Hdpza)2(H2O)2](ClO4)2 (2); anti–syn